AI designs peptides for ‘undruggable’ diseases
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
List view / Grid view
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
Download our latest report to discover how stem cell research is revolutionising treatments for chronic diseases, cancer and regenerative medicine.
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
Researchers at the University of Chicago have revealed the complete structure of adhesion GPCRs, uncovering new activation mechanisms that could lead to more targeted drug treatments.
The LiCellGrow cell expansion system enables real-time metabolic monitoring and automated culture optimisation to accelerate cell and gene therapy manufacturing.
Learn how the University at Buffalo is pioneering safer, more effective ADC therapies.
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
Cancer Research Horizons has teamed up with Diamond Light Source to drive the discovery of new cancer treatments.
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
The global small molecule drug discovery market is set for significant growth. Explore the key factors driving this expansion, from rising R&D investments to the increasing role of AI and CROs.
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
The 2024 Nobel Prize in Chemistry honours AI's transformative impact on protein science, with breakthroughs set to reshape drug development.